Clinical trial · Interventional
Lifei Xiaoji Wan in Treatment of Advanced NSCLC
Clinical Efficacy of Lifei Xiaoji Wan in Treatment of Advanced NSCLC
NCT06406166CI-TRIAL-00081021unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to evaluate the clinical efficacy of Lifei Xiaoji Wan for advanced non-small cell lung cancer (NSCLC), establish the treatment scheme, and obtain high-quality clinical evidence.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conventional treatment with Western medicine | Other | — | UNRESOLVED |
| Lifei Xiaoji Wan | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- trial group
- description
- The patients in the trial group received routine Western medicine treatments, and oral Lifei Xiaoji Wan (10 pills/time, 3 times/day).
- interventionNames
- Drug: Lifei Xiaoji Wan
- Other: Conventional treatment with Western medicine
- type
- NO_INTERVENTION
- label
- control group
- description
- The patients in the control group received routine Western medicine treatments.
Primary outcomes (2)
- measure
- Overall survival
- timeFrame
- From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 1 year.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Clinical diagnosis of NSCLC. 2. The tumor stage (TNM) stage is from III to IV. 3. 18-80 years old. 4. The expected survival period is\> 3 months. Exclusion Criteria: 1. Early-stage patients with prior surgery and no recurrence. 2. Patients with serious dysfunction of the heart, liver, heart, kidney, and other important organs. 3. Mental illness and other patients were unable to complete the study.
References
Publications (0)
Data not yet available
No reference posted for this study.